Cancer stem cells, microRNAs, and therapeutic strategies including natural products (Q38023238)

27 August 2017

title

Cancer stem cells, microRNAs, and therapeutic strategies including natural products (English)

1 reference

27 August 2017

1 reference

1 reference

neoplastic stem cells

1 reference

6

Eri S Srivatsan

1 reference

27 August 2017

3

Mysore S Veena

1 reference

27 August 2017

4

Marilene B Wang

1 reference

27 August 2017

Darshni Vira

1

1 reference

27 August 2017

Saroj K Basak

series ordinal

2

1 reference

27 August 2017

Raj K Batra

series ordinal

5

1 reference

27 August 2017

publication date

1 December 2012

1 reference

Cancer and Metastasis Reviews

27 August 2017

published in

1 reference

27 August 2017

volume

31

1 reference

27 August 2017

issue

3-4

1 reference

27 August 2017

page(s)

733-751

1 reference

Cancer stem cells: implications for the progression and treatment of metastatic disease.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

CTIP2 expression in human head and neck squamous cell carcinoma is linked to poorly differentiated tumor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: models and concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Human colon cancer stem cells: a new paradigm in gastrointestinal oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells and impaired apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in head and neck squamous cell carcinoma: a review of current knowledge and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The stem cell hypothesis in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A stem cell gene expression profile of human squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Role of "cancer stem cells" and cell survival in tumor development and maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: an old idea--a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells in squamous head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Distinct epigenetic profiling in head and neck squamous cell carcinoma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Breast cancer stem cells: treatment resistance and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Epigenetic regulation of normal and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Targeting breast cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Evolution of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: a new framework for the design of tumor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cell concepts renew cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

21 January 2018

Stem cells and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: AMLs show the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: lessons from leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Identification and targeting of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells in normal breast development and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Therapeutic implications of cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in bladder cancer: a revisited and evolving concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

An Overview of Concepts for Cancer Stem Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Recent advances in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Therapeutic implications of the cancer stem cell hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Defining new paradigms for the treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Urothelial cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells and cancer of the stomach and intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in urologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Immunoregulatory properties of CD44+ cancer stem‐like cells in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Epithelial-mesenchymal transition in cancer development and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

CD44s and CD44v6 expression in head and neck epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in head and neck squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

CD133, one of the markers of cancer stem cells in Hep-2 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A cancer stem cell origin for human endometrial carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Lung cancer stem cells: tools and targets to fight lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in solid tumors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells and self-renewal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Pancreatic cancer stem cells and relevance to cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells in cancer: instigators and propagators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Pancreatic cancer stem cells - update and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Pancreatic cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Properties and identification of cancer stem cells: a changing insight into intractable cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: Models, mechanisms and implications for improved treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Liver stem cells and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Tumor-initiating stem cells in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Novel therapeutic strategies for targeting liver cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

21 January 2018

Liver cancer stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells and cancer: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The cancer stem cell: premises, promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: problems for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Liver cancer stem cells: implications for a new therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

ALDH1 as a functional marker of cancer stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

More than markers: biological significance of cancer stem cell-defining molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in breast cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The role of human aldehyde dehydrogenase in normal and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells: a novel paradigm for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Human pyruvate kinase M2: a multifunctional protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cellular senescence and tumor suppressor gene p16

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Complex networks orchestrate epithelial-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Twist-ing cell fate: mechanistic insights into the role of twist in lineage specification/differentiation and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Bmi1 is essential in Twist1-induced epithelial–mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Potential therapeutic implications of cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Side population cells isolated from mesenchymal neoplasms have tumor initiating potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Head and neck cancer stem cells: the side population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Human ovarian cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Identification of bronchioalveolar stem cells in normal lung and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cancer stem cells in lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Side population and cancer stem cells: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Identification of cancer stem cell-related microRNAs in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Functional analysis of microRNAs in human hepatocellular cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Differentially expressed microRNAs in pancreatic cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

let-7 regulates self renewal and tumorigenicity of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The role of PARP in DNA repair and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

PARP inhibitor treatment in ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

An emerging role for TOR signaling in mammalian tissue and stem cell physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Molecular targeted therapy for hepatocellular carcinoma: bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Mammalian target of rapamycin and head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

mTOR inhibitors in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The Role of ABC Transporters in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Targeting glioma stem cells: a novel framework for brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Therapeutic strategies by modulating oxygen stress in cancer and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Molecular basis for the actions of Hsp90 inhibitors and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Implication of microRNAs in drug resistance for designing novel cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Multi-targeted prevention of cancer by sulforaphane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Targeting breast stem cells with the cancer preventive compounds curcumin and piperine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cucurbitacin: ancient compound shedding new light on cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Strategies to eliminate cancer stem cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Oncolytic adenoviruses targeted to cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

Identification of a tumor-initiating stem cell population in human renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9382-8

10.1007/S10555-012-9382-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1007342568

0 references

1 reference